F. Hoffmann-La Roche Ltd: FDA approves Roche's Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma

Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of non-Hodgkin lymphoma

Related Keywords

Switzerland ,United States ,Lugano ,Ticino ,Japan ,America ,Mabthera Rituxan ,Bruno Eschli ,Sabine Borngr ,Nathalie Altermatt ,Birgit Masjost ,Loren Kalm ,Levi Garraway ,Gerard Tobin ,Roche Group Media Relations ,Lymphoma Academic Research Organisation ,Roche Group ,Head Of Global Product Development ,Lymphoma Study Association ,International Prognostic Index ,Genentech ,Drug Administration ,Chief Medical Officer ,Global Product ,Lugano Response Criteria ,Lymphoma Academic Research ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Hoffmann ,Oche ,Pproves ,Polivy ,Combination ,People ,Certain ,Types ,Reviously ,Untreated ,Diffuse ,Barge ,Fell ,Lymphoma ,